Which patients are best treated with decavatinib for psoriasis?

Deucravacitinib (deucravatinib) is an oral selective TYK2 inhibitor mainly used to treat moderate to severe plaque psoriasis. Its mechanism of action is to reduce keratinocyte proliferation and skin inflammation from the source by inhibiting inflammatory signals mediated by IL-23/IL-12, thereby improving skin symptoms. The oral delivery method makes it a new option for patients who are not suitable for injection or long-term topical treatment.

Patients with moderate to severe plaque psoriasis who do not respond well to topical medications are ideal candidates for decavatinib. Such patients are often accompanied by extensive skin lesions and significant itching, and it is difficult to obtain sustained improvement through topical glucocorticoids or vitamin Aacid drugs. Oral decarvatinib can systematically regulate immune inflammation, improve serum and skin inflammation indicators, and thereby more effectively relieve symptoms.

This drug is also suitable for patients who are unwilling or unsuitable for biologic injections. Traditional anti-TNF-α or anti-IL-17 biological agents require subcutaneous injection or intravenous infusion. Some patients are afraid of injections or have long-term inconvenience in medical treatment. Decavatinib is easy to take orally and can be taken continuously in a home environment while avoiding injection-related discomfort and complications and facilitating compliance management.

It is also suitable for use in patients with comorbidities who require caution in immunosuppression. Decavatinib has mild suppression of the immune system and a relatively low risk of infection, and is suitable for patients with mild to moderate cardiovascular disease, metabolic syndrome, or mild liver and kidney dysfunction. During use, hematology, liver and kidney function still need to be monitored regularly under the guidance of a doctor to ensure safety. In summary, decavatinib is suitable for patients with moderate to severe psoriasis who have poor efficacy of external application, who wish to receive oral treatment, and who need to avoid strong immunosuppression.

Reference materials:https://www.drugs.com/